+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

The CEO of Zenefits just went on a tweet rant about how it's not the next Theranos

May 21, 2016, 03:29 IST

Advertisement
Zenefits COO David SacksZenefits

David Sacks, the CEO of troubled startup Zenefits thinks it's unfair that the press has been lumping it into the same category as troubled startup Theranos.

He went on a whole Twitter rant about it on Friday, linking to this story in the LA Times about how startups that claim to be "disruptive" are often mostly hype.

The reporter, Michael Hiltzikin, starts with Theranos, which has become the poster child for highly funded, highly valued startups that have run afoul. 

Hiltzikin points out the company's run-in with regulators who have questioned the accuracy of its one-drop-of-blood blood testing technology. (Theranos has recalled the test results from its blood machines, the Wall Street Journal recently reported.)

The reporter then notes that Zenefits is another high-flying startup that ran afoul of regulators, who have been investigating the company for selling insurance without a license.

Advertisement

In Zenefits case, its CEO resigned over the matter, and the company than revealed details of how that CEO created a program that may have let employees skirt the law when studying for their licenses.

Sacks basically accused the reporter of being "lazy."

It documented all the ways he changed the company since he took over as CEO on February 8, when founder Parker Conrad resigned. (Sacks had been with the company as COO since December 2014.)

Advertisement
Theranos CEO Elizabeth Holmes speaks on stage at the Glamour Women of the Year Awards where she receives an award, in the Manhattan borough of New YorkThomson Reuters

Here's his whole rant:

Unlike others, we have fixed our licensing issues. These are historical issues, not current ones. Today we are operating in compliance. 

Unlike others, we self-reported these historical licensing issues to regulators. We've been open and transparent about past failings. Today we are operating in compliance. 

Unlike others, we reconstituted our board of directors to provide proper oversight and corporate governance. 

Unlike others, we have stood up a robust compliance organization to prevent these issues from happening again.

Advertisement

Unlike others, we proactively commissioned a Big Four accounting firm to audit our licensing and shared the result with regulators.

Unlike others, we have made compliance a central part of our culture, values and expertise moving forward.

Most of all, we have a real product that works for many thousands of small businesses who express appreciation and gratitude.

As a result, our customer base (over 20,000) is sticking with us and ARR remains over $60M.

In summary, Zenefits today is a different company that has addressed its historical issues and is looking to the future.

Advertisement

To his credit, it is hard to clean up a troubled company with more than 1,000 employees whose products are used by 20,000 customers - and do it in the public eye.

On the other hand, Zenefits' problems were not exactly the messenger's fault and it might take more than a couple of months to prove itself a comeback story.

NOW WATCH: Humans are defying the law of evolution

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article